Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 May 14

PMID 35565202

Authors

Petr Busek

Jonathan S Duke-Cohan

Aleksi Sedo

Affiliations

Soon will be listed here.

Abstract

Dipeptidyl peptidase IV (DPP-IV, CD26) is frequently dysregulated in cancer and plays an important role in regulating multiple bioactive peptides with the potential to influence cancer progression and the recruitment of immune cells. Therefore, it represents a potential contributing factor to cancer pathogenesis and an attractive therapeutic target. Specific DPP-IV inhibitors (gliptins) are currently used in patients with type 2 diabetes mellitus to promote insulin secretion by prolonging the activity of the incretins glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Nevertheless, the modulation of the bioavailability and function of other DPP-IV substrates, including chemokines, raises the possibility that the use of these orally administered drugs with favorable side-effect profiles might be extended beyond the treatment of hyperglycemia. In this review, we critically examine the possible utilization of DPP-IV inhibition in cancer prevention and various aspects of cancer treatment and discuss the potential perils associated with the inhibition of DPP-IV in cancer. The current literature is summarized regarding the possible chemopreventive and cytotoxic effects of gliptins and their potential utility in modulating the anti-tumor immune response, enhancing hematopoietic stem cell transplantation, preventing acute graft-versus-host disease, and alleviating the side-effects of conventional anti-tumor treatments.

Citing Articles

Synthetic Approaches to Novel DPP-IV Inhibitors-A Literature Review.

Petrov V, Aleksandrova T, Pashev A Molecules. 2025; 30(5).

PMID: 40076268 PMC: 11902039. DOI: 10.3390/molecules30051043.

Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies.

Bayanati M, Ismail Mahboubi Rabbani M, Sirous Kabiri S, Mir B, Rezaee E, Tabatabai S Iran J Pharm Res. 2025; 23(1):e151581.

PMID: 40066124 PMC: 11892788. DOI: 10.5812/ijpr-151581.

Unlocking the mechanistic potential of for managing diabetic neuropathy and nephropathy.

Singh S, Singh T J Tradit Complement Med. 2025; 14(6):581-597.

PMID: 39850604 PMC: 11752125. DOI: 10.1016/j.jtcme.2024.04.009.

Anti-Diabetic Therapies and Cancer: From Bench to Bedside.

Kounatidis D, Vallianou N, Karampela I, Rebelos E, Kouveletsou M, Dalopoulos V Biomolecules. 2024; 14(11).

PMID: 39595655 PMC: 11591849. DOI: 10.3390/biom14111479.

Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review.

Buczynska A, Kosciuszko M, Kretowski A, Poplawska-Kita A Front Pharmacol. 2024; 15:1323083.

PMID: 38292938 PMC: 10824900. DOI: 10.3389/fphar.2024.1323083.

References

Arscott W, LaBauve A, May V, Wesley U . Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation. Oncogene. 2008; 28(4):479-91. PMC: 2633428. DOI: 10.1038/onc.2008.402. View

Batchu S, Yerra V, Liu Y, Advani S, Klein T, Advani A . The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans. Int J Mol Sci. 2020; 21(16). PMC: 7460951. DOI: 10.3390/ijms21165756. View

Hsu W, Sue S, Liang H, Tseng C, Lin H, Wen W . Dipeptidyl Peptidase 4 Inhibitors Decrease the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Infection and Type 2 Diabetes Mellitus: A Nationwide Study in Taiwan. Front Public Health. 2021; 9:711723. PMC: 8484707. DOI: 10.3389/fpubh.2021.711723. View

Rathmann W, Kostev K . Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer. J Diabetes Complications. 2017; 31(4):687-692. DOI: 10.1016/j.jdiacomp.2017.01.012. View

Kim S, Yoo J, Lee W, Park C . Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus. Diabetes Metab J. 2016; 40(5):339-353. PMC: 5069390. DOI: 10.4093/dmj.2016.40.5.339. View

Dicembrini I, Nreu B, Montereggi C, Mannucci E, Monami M . Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Acta Diabetol. 2020; 57(6):689-696. DOI: 10.1007/s00592-020-01479-8. View

Kim S, Kang J, Kim C, Ihm S, Choi M, Yoo H . Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells. J Endocrinol Invest. 2017; 41(6):677-689. DOI: 10.1007/s40618-017-0792-x. View

Yorifuji N, Inoue T, Iguchi M, Fujiwara K, Kakimoto K, Nouda S . The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice. Oncol Rep. 2015; 35(2):676-82. DOI: 10.3892/or.2015.4429. View

Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G . Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood. 2001; 98(13):3554-61. DOI: 10.1182/blood.v98.13.3554. View

10.

Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M . (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared.... J Pharmacol Exp Ther. 2008; 325(1):175-82. DOI: 10.1124/jpet.107.135723. View

11.

Butler A, Campbell-Thompson M, Gurlo T, Dawson D, Atkinson M, Butler P . Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013; 62(7):2595-604. PMC: 3712065. DOI: 10.2337/db12-1686. View

12.

Lee J, Wang T, Liu C, Chien M, Chen M, Hsu Y . Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017; 102(8):2930-2940. DOI: 10.1210/jc.2017-00346. View

13.

Henderson J, Xiang M, Huang J, Wetzel S, Jiang L, Lai J . Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma. Cancers (Basel). 2021; 13(21). PMC: 8583374. DOI: 10.3390/cancers13215495. View

14.

Busek P, Stremenova J, Sromova L, Hilser M, Balaziova E, Kosek D . Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity. Int J Biochem Cell Biol. 2012; 44(5):738-47. DOI: 10.1016/j.biocel.2012.01.011. View

15.

Zhang M, Xu L, Wang X, Sun B, Ding J . Expression levels of seprase/FAPα and DPPIV/CD26 in epithelial ovarian carcinoma. Oncol Lett. 2015; 10(1):34-42. PMC: 4487033. DOI: 10.3892/ol.2015.3151. View

16.

Khalil R, Shata A, Abd El-Kader E, Sharaf H, Abdo W, Amin N . Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38α, and NF-κB signaling. Toxicol Appl Pharmacol. 2020; 407:115246. DOI: 10.1016/j.taap.2020.115246. View

17.

Beckenkamp A, Davies S, Willig J, Buffon A . DPPIV/CD26: a tumor suppressor or a marker of malignancy?. Tumour Biol. 2016; 37(6):7059-73. DOI: 10.1007/s13277-016-5005-2. View

18.

Kim S, Kang J, Kim C, Ihm S, Choi M, Yoo H . Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells. Endocrine. 2017; 59(2):383-394. DOI: 10.1007/s12020-017-1503-2. View

19.

Lu Z, Qi L, Bo X, Liu G, Wang J, Li G . Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters. J Res Med Sci. 2014; 18(8):647-52. PMC: 3872602. View

20.

Duarte R, Labopin M, Bader P, Basak G, Bonini C, Chabannon C . Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019; 54(10):1525-1552. DOI: 10.1038/s41409-019-0516-2. View